Impact of critical process parameters on the dimensional, mean weight, and swelling properties of 3D-printed intravaginal rings: a quality by design approach.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Gabrielle Silva de Campos Lazzarini, Guilherme Luíz Da Silva, Laís S Lacerda, Anna Lectícia M Martinez Toledo, Thaís Nogueira Barradas
{"title":"Impact of critical process parameters on the dimensional, mean weight, and swelling properties of 3D-printed intravaginal rings: a quality by design approach.","authors":"Gabrielle Silva de Campos Lazzarini, Guilherme Luíz Da Silva, Laís S Lacerda, Anna Lectícia M Martinez Toledo, Thaís Nogueira Barradas","doi":"10.1080/10837450.2025.2462945","DOIUrl":null,"url":null,"abstract":"<p><p>3D printing is emerging as a transformative technology in pharmaceutical manufacturing, enabling personalized medicine and innovative dosage forms. It allows precise control over drug release and dosage customization, addressing individual patient needs. Various 3D printing techniques, including fused deposition modeling (FDM), are being explored for pharmaceutical applications. The choice of polymers and their rheological properties is crucial for successful extrusion-based printing. While 3D printing accelerates drug development, challenges remain regarding quality control. Quality-by-design (QbD) approaches are essential to ensure safe and effective pharmaceutical products. This study highlights the role of critical process parameters (CPPs), such as infill density and printing speed, in producing poly(lactic acid)-based intravaginal rings. The effects of CPPs on critical quality attributes (CQAs), such as ring dimensions, weight, and swelling degree, were examined. Printing speed (25-100 mm/s) and infill density (0-20%) significantly affected weight and dimensions, with average weights ranging from 0.537 g to 0.629 g. Internal dimensions varied between 9.73 mm and 9.81 mm, while external dimensions ranged from 19.43 mm to 19.69 mm. Rings printed at the lowest speed and highest infill density showed the greatest swelling (2.47%). These findings confirm FDM as a viable method for producing cost-effective, patient-specific intravaginal rings with reproducible results.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"186-194"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Development and Technology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10837450.2025.2462945","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

3D printing is emerging as a transformative technology in pharmaceutical manufacturing, enabling personalized medicine and innovative dosage forms. It allows precise control over drug release and dosage customization, addressing individual patient needs. Various 3D printing techniques, including fused deposition modeling (FDM), are being explored for pharmaceutical applications. The choice of polymers and their rheological properties is crucial for successful extrusion-based printing. While 3D printing accelerates drug development, challenges remain regarding quality control. Quality-by-design (QbD) approaches are essential to ensure safe and effective pharmaceutical products. This study highlights the role of critical process parameters (CPPs), such as infill density and printing speed, in producing poly(lactic acid)-based intravaginal rings. The effects of CPPs on critical quality attributes (CQAs), such as ring dimensions, weight, and swelling degree, were examined. Printing speed (25-100 mm/s) and infill density (0-20%) significantly affected weight and dimensions, with average weights ranging from 0.537 g to 0.629 g. Internal dimensions varied between 9.73 mm and 9.81 mm, while external dimensions ranged from 19.43 mm to 19.69 mm. Rings printed at the lowest speed and highest infill density showed the greatest swelling (2.47%). These findings confirm FDM as a viable method for producing cost-effective, patient-specific intravaginal rings with reproducible results.

关键工艺参数对3d打印阴道内环尺寸、平均重量和膨胀特性的影响:一种质量设计方法。
3D打印已经成为制药制造领域的一项变革性技术,为个性化医疗和创新剂型提供了潜力。它可以精确控制药物释放概况和剂量定制,解决个别患者的需求。各种3D打印技术,包括熔融沉积建模(FDM),正在探索用于制药应用。聚合物的选择及其流变特性对于成功的基于挤出的3D打印药物至关重要。虽然3D打印在加速药物开发和促进大规模生产方面显示出希望,但在质量和质量控制方面仍然存在挑战。用于开发3d打印剂型的质量设计(QbD)方法对于评估药物含量、释放谱和整体质量以确保药品安全有效至关重要。在这项研究中,我们强调了关键工艺参数(CPPs)的作用,如填充密度和打印速度在生产基于聚乳酸的阴道内环。研究了CPPs对环尺寸、平均重量和膨胀度等关键质量属性的影响。本研究利用方差分析方法评估了打印速度(25-100 mm/s)和填充密度(0-20%)对3d打印环的重量和尺寸的影响。结果表明,打印设置对重量和尺寸都有显著影响。平均重量为0.537 g ~ 0.629 g,填充密度最高、打印速度最低的样品重量最大。内圈尺寸在9.73 ~ 9.81 mm之间,外圈尺寸在19.43 ~ 19.69 mm之间。在溶胀试验中,在pH为4.3的蒸馏水中,打印速度最低、填充密度最高的环在3小时后溶胀最大,达到2.47%。填充密度和打印速度对阴道内环的尺寸、重量和膨胀行为产生关键影响。结果表明,FDM提供了一种可行的方法来生产具有成本效益的、患者特异性的阴道内环,统计分析证实了所制造装置的可重复性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
2.90%
发文量
82
审稿时长
1 months
期刊介绍: Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology. Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as: -Preformulation and pharmaceutical formulation studies -Pharmaceutical materials selection and characterization -Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation -QbD in the form a risk assessment and DoE driven approaches -Design of dosage forms and drug delivery systems -Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies -Drug delivery systems research and quality improvement -Pharmaceutical regulatory affairs This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信